Drug Approvals, Breakthrough Treatments and Royalties - Research Report on Celgene Corporation, Onyx Pharmaceuticals, Sarepta Therapeutics, VIVUS and Achillion Pharmaceuticals

NEW YORK, March 8, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), VIVUS Inc. (NASDAQ: VVUS) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

The optimism for Celgene has been pushing the stock to trade on the green in recent sessions. Celgene was hailed by the European Organization for Rare Diseases (EURODIS) for its excellence in medical innovation in rare diseases. The company is now considered as the leader in the treatment of rare illnesses, such as cancer and other severe, immune and inflammatory conditions. Celgene also received positive results for oral Apremilast after it achieved statistical significance for the primary endpoint of PASI-75 in the first Phase III study (ESTEEM 1) in patients with Psoriasis. Celgene is expecting annual revenue of $12 billion by 2017. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:[http://www.Investors-Alliance.com/r/full_research_report/d457_CELG ]

--

Onyx Pharmaceuticals, Inc. Research Report

After Onyx reported new sales record for its Kyprolis, the company's first wholly-owned product, carcinoma-treatment Nexavar posted strong regional growth as it exceeded $1 billion in sales. Onyx looks poised for long-term growth after the US Food and Drug Administration (FDA) approved Stivarga. In 2012, Onyx received $8 million in royalty revenues from Bayer for the total sales of Stivarga. The FDA approval is expected to rake in bigger royalties for Onyx while the company continues its research and development for breakthrough treatments. The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/ffcf_ONXX]

--

Sarepta Therapeutics, Inc. Research Report

Finding a treatment for Marburg Virus, a severe and potentially fatal disease classified as a Category A bioterrorism agent, is a great challenge to Sarepta as it collaborates with the US Army Medical Research Institute to formulate a cure for the hemorrhagic fever. Sarepta's AVI-7288 received positive results after conducting a non-human primate study to test the efficacy of the drug. The company administered AVI-7288 via intramuscular injection which is considered as the best way to utilize the cure in a mass casualty situation. The success of AVI-7288 is expected to be massive once it is approved by the FDA since its major clients may include various governments and Africa where Marburg Virus is considered an endemic. The Full Research Report on Sarepta Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/cfa4_SRPT]

--

VIVUS Inc. Research Report

Qsymia, considered as one of the most successful obesity treatments from VIVUS, showed great results after a study on weight loss and cardiovascular disease risk factors. VIVUS reported that weight loss resulting from treatment with Qsymia helped the improvement of cholesterol, blood pressure and triglycerides related conditions. The positive results were greater among patients who recorded an average of 10% in weight loss. VIVUS is expected to earn a bigger market share because of this breakthrough obesity treatment. The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:[http://www.Investors-Alliance.com/r/full_research_report/8ed8_VVUS]

--

Achillion Pharmaceuticals, Inc. Research Report

Achillion is conducting the Phase II clinical trial consisting of sovaprevir and ACH-3102 during the second quarter of 2013. The company has been actively working up its research and development to gain new approvals from the US Food and Drug Administration (FDA). Achillion is one of the leading companies for the research and development of Hepatitis C Virus (HCV) treatments. The company is known for developing small molecule drugs for the treatment of the most challenging infectious diseases. The Full Research Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/0af0_ACHN]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: [email protected]
Main: +1-(480)-745-7826

SOURCE Investors-Alliance